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RELATED APPLICATIONS
This application claims priority from U.S. Provisional
Application Ser. No. 61/586,427 filed Jan. 13, 2012, the
entire disclosure of which is incorporated herein by this
reference.

5

10

GOV ERNMENT INTEREST
This invention was made with govermnent support under
Grant No. EY 022238-01 awarded by the National Institutes
of Health.

15

TECHNICAL FIELD
The presently-disclosed subject matter relates to thera
peutic uses of inflammasome inhibition, P2X7 inhibition,
and inhibition of IRAKl and/or IRAK4, methods protecting
a cell, and screening methods for identifying inhibitors.
INTRODUCTION
Age-related macular degeneration (AMD) is a devastating
disease that affects the vision of tens of millions of indi
viduals worldwide (Smith et al., 2001). AMD is character
ized by dysfunction and degeneration of the retinal pig
mented epithelium (RPE), a highly specialized monolayer of
cells that is interposed between the retinal photoreceptors
and the choroidal capillaries (Ambati et al., 2003). RPE
dysfunction can lead to anatomical and functional disruption
of both the photoreceptors and the choroidal vasculature
(Blaauwgeers et al., 1999; Lopez et al., 1996; McLeod et al.,
2009; Vogt et al., 2011). These tissue architecture disrup
tions lead to atrophic or neovascular disease phenotypes.
Although there are multiple approved therapies for the
neovascular form of AMD (Ferrara, 2010), there is no
effective treatment for the far more common atrophic form
of the disease. GA, the advanced stage of atrophic AMD, is
characterized by degeneration and death of the RPE, and is
the leading cause of untreatable vision loss.
Recently, it was shown that a dramatic and specific
reduction of the RNase DICER! results in accumulation of
Alu RNA transcripts in the RPE of human eyes with GA
(Kaneko et al., 2011; International Patent Application No.
PCT/USll/38753, Ambati). These repetitive element transcripts, which are non-coding RNAs expressed by the highly
abundant Alu retrotransposon (Batzer and Deininger, 2002),
induce human RPE cell death and RPE degeneration in
mice. DICER! deficit in GA RPE was not a generic cell
death response because DICER! expression was not dysregulated in a variety of other retinal diseases. Likewise, Alu
RNA accumulation did not represent generalized retrotrans
poson activation due to a stress response in dying cells
because several other retrotransposons were not elevated in
GA RPE, DICER! is central in the biogenesis of mature
microRNAs (Bernstein et al., 2001). Yet, intriguingly, fol
lowing DICER! deficit, the accumulation of Alu RNA
transcripts and not the lack of mature microRNAs was the
critical determinant of RPE cell viability (Kaneko et al.,
2011). Moreover, other RNAs of similar length such as 7SL
RNA, transfer RNA, and primary microRNAs do not induce
RPE degeneration (Kaneko et al., 2011), ruling out a non-
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specific toxicity of excess, highly structured RNA. Still, the
precise mechanisms of Alu RNA-induced cytotoxicity are
unknown.
Although the retina is a tissue exceptional for its immune
privilege (Streilein, 2003), its hypersensitive response to
exogenous insults mediated by innate immune sensors can
result in profound inflammation. The three major classes of
innate immune receptors include the toll-like receptors
(TLRs), retinoic acid inducible gene I (RIG-I)-like helicases,
and nucleotide-binding domain and leucine-rich-repeat-con
taining (NLR) proteins (Akira et al., 2006). Numerous
innate immune receptors have been identified in the RPE
(Kumar et al., 2004), and a variety of exogenous substances
can induce retinal inflammation (Allensworth et al., 2011;
Kleinman et al., 2011). However, it is not known whether
this surveillance machinery recognizes or responds to host
endogenous RNAs. As described herein, the present inventor
explored the concept that innate immune machinery, whose
canonical function is the detection of pathogen associated
molecular patterns and other moieties from foreign organ
isms, might also recognize cytotoxic Alu RNA.
As described herein, it was shown that Alu transcripts can
hijack innate immunity machinery to induce RPE cell death.
Surprisingly, the data set forth herein show that DICER!
deficit or Alu RNA activates the NLRP3 inflammasome in a
MyD88-dependent, but TLR-independent manner. Until
now, NLRP3 inflammasome activation in vivo has been
largely restricted to immune cells, although the findings
open the possibility that NLRP3 inflammasome activity may
be more widespread than previously thought, as reflected by
examples in cell culture studies of keratinocytes (Feldmeyer
et al., 2007; Keller et al., 2008). The findings disclosed
herein also broaden the scope of DICER! function beyond
microRNA biogenesis, and identify its role as a guardian
against the aberrant overexpression of toxic retrotransposon
genetic elements that comprise roughly 50% of the human
genome (Lander et al., 2001). The findings present a novel
self-recognition immune response, whereby endogenous
non-coding RNA-induced NLRP3 inflammasome activation
results from DICER! deficiency in a non-immune cell. Also
proposed herein are unique targets for protecting RPE cells
against cell death, including P2X7 activation and IRAK-1/4.
SUMMARY
The presently-disclosed subject matter meets some or all
of the above-identified needs, as will become evident to
those of ordinary skill in the art after a study of information
provided in this document.
This S=ary describes several embodiments of the
presently-disclosed subject matter, and in many cases lists
variations and permutations of these embodiments. This
Summary is merely exempl ary of the numerous and varied
embodiments. Mention of one or more representative fea
tures of a given embodiment is likewise exemplary. Such an
embodiment can typically exist with or without the
feature(s) mentioned; likewise, those features can be applied
to other embodiments of the presently-disclosed subject
matter, whether listed in this Summary or not. To avoid
excessive repetition, this Summary does not list or suggest
all possible combinations of such features.
The presently-disclosed subject matter includes a method
of protecting a cell, which involves inhibiting one or more
of P2X7 activation associated with or in the cell, inhibiting
IRAKl associated with or in the cell; or inhibiting IRAK4
associated with or in the cell.
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In some embodiments, the cell is an RPE cell, a retinal
photoreceptor, or a choroidal cell. In some embodiments, the
cell is in a subject. In some embodiments, the cell is an RPE
cell, and the method also involves identifying a subject for
which protection of the RPE cell is desired. In some embodiments, the cell is an RPE cell is of a subject having
age-related macular degeneration. In some embodiments,
contacting the cell with an inhibitor comprises administering
the inhibitor to a subject.
In some embodiments of the method, the inhibiting of
P2X7 activation includes contacting the cell with a P2X7
activation inhibitor, e.g., P2X7 receptor antagonist
A438079.
In some embodiments of the method, inhibiting IRAKl
and/or IRAK 4 includes contacting the cell with an IRAKl
and/or IRAK4 inhibitor (e.g., N-(2-Morpholinylethyl)-2-(3nitrobenzoylamido)-benzimidazole).
In some embodiments the method can also include inhib
iting MyD88 associated with or in the cell; inhibiting IL-18
associated with or in the cell; inhibiting an inflammasome
associated with or in the cell; increasing levels of a DICER
polypeptide associated with or in the cell; and/or inhibiting
AluRNA associated with or in the cell.
The presently-disclose d subject matter also includes a
method of treating macular degeneration, which involves
identifying a subject in need of treatment for macular
degeneration; and inhibiting P2X7 activation associated
with or in a cell of the subject; inhibiting IRAKl associated
with or in a cell of the subject; inhibiting IRAK4 associated
with or in a cell of the subject; inhibiting MyD88 associated
with or in the cell; inhibiting IL-18 associated with or in the
cell; inhibiting an inflammasome associated with or in the
cell; increasing levels of a DICER polypeptide associated
with or in the cell; and/or inhibiting AluRNA associated with
or in the cell.
In some embodiments of the method, the inhibiting
MyD88 associated with or in the cell includes contacting the
cell with a MyD88 inhibitor. In some embodiments of the
method, the inhibiting of P2X7 activation includes contact
ing the cell with a P2X7 activation inhibitor (e.g., P2X7
receptor antagonist A438079). In some embodiments of the
method, the inhibiting IRAKl and/or IRAK 4 includes
contacting the cell with an IRAKl and/or IRAK4 inhibitor
( e.g.,
N-(2-Morpholinylethyl)-2-(3-nitrobenzoylamido)benzimidazole).
The presently-disclosed subject matter further includes
kits useful for practicing methods as disclosed herein. In
some embodiments, the kit includes a P2X7 activation
inhibitor, packaged together with an IRAKl and/or IRAK4
inhibitor. In some embodiments, the kit also includes a
MyD88 inhibitor, an IL-18 inhibitor, an inflammasome
inhibitor, a DICER polypeptide, and an AluRNA inhibitor.
The presently-disclosed subject matter further includes a
method of identifying an IRAKl and/or IRAK4 inhibitor,
which involves providing a cultured cell wherein phospho
rylated IRAKl and/or IRAK4 is upregulated; contacting the
cell with a candidate compound; and determining whether
the candidate compound results in a change in the IRAKl
and/or IRAK4. In some embodiments, the IRAKl and/or
IRAK4 is upregulated by stimulating the cell with a MyD88
activator. In some embodiments, the method further includes
measuring phosphorylation of IRAKl and/or IRAK4 by
Western Blotting. In some embodiments, the change in the
IRAKl and/or IRAK4 is monitored by measuring cell
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viability, or measuring the expression of a gene known to be
induced by IRAKl and/or IRAK 4 signaling.
5

10

15

20

25

30

35

40

45

50

55

60

65

BRIEF DESCRIPTION OF THE DRAWINGS
The novel features of the invention are set forth with
particularity in the appended claims. A better understanding
of the features and advantages of the present invention will
be obtained by reference to the following detailed descrip
tion that sets forth illustrative embodiments, in which the
principles of the invention are used, and the accompanying
drawings of which:
FIG. 1. Alu RNA does not activate or function via toll-like
receptors (TLRs). (A-E) Subretinal injection of a plasmid
coding for Alu RNA (pAlu), but not pNull, induces retinal
pigmented epithelium (RPE) degeneration in wild-type mice
(A) and in mice deficient in Tlr3 (B) or Tlr7 (C), mice with
a mutation (mt) in Unc93bl (D), which are functionally
deficient in TLRs-3,7,9, or deficient in Tlr4 (E). Representative images shown. n=S-12. Fundus photographs, top row;
Flat mounts stained for zonula occludens-1 (Z0-1; red),
bottom row. Degeneration outlined by blue arrowheads.
Scale bars, 20 µm. (F) Stimulation of HEK293 cell lines
expressing various TLRs with either of two different Alu
RNA sequences does not elicit NF-KB activation as assessed
by measuring a secreted alkaline phosphatase reporter under
the control of a NF-KB-inducible promoter. Positive (+)
controls using TLR-specific ligands activated NF-KB. n=3.
FIG. 2. Alu RNA does not activate several RNA sensors.
(A and B) p7SL (a 7SL expression vector) (A) and in vitro
synthesized 7SL RNA (B) do not induce RPE degeneration
in wild-type mice. (C) RPE degeneration induced by sub
retinal injection of pAlu in wild-type mice is not blocked by
a TLR4 antagonist. (D-E) Mice deficient in Mda5 (D) or
Prkr (E) are susceptible to pAlu-induced RPE degeneration.
(F) Dephosphorylated (Dep) Alu RNA induces RPE degen
eration in wild-type mice just as well as Alu RNA. (G) Mice
deficient in Mays are susceptible to pAlu-induced RPE
degeneration. pNull does not induce RPE degeneration in
any strain of mice. Degeneration outlined by blue arrow
heads. Fundus photographs, top rows; Z0-1 stained (red)
RPE flat mounts, bottom rows. n=S (A-G). (H) A schematic
of the innate immune pathways that are not activated by Alu
RNA.
FIG. 3. Alu RNA induces RPE degeneration via MyD88.
(A) pAlu does not induce RPE degeneration in Mydss-1mice. (B) pAlu-induced RPE degeneration in wild-type mice
is inhibited by a MyD88 homodimerization peptide inhibitor
(MyD88i), but not by a control peptide. (C) pAlu-induced
RPE degeneration in wild-type mice is inhibited by intrav
itreous cholesterol-conjugated Myd88 siRNA but not cholesterol-conjugated control siRNA. (D and E) siRNA target
ing MyD88 (siMyD88) reduces target gene (D, real-time
RT-PCR) and protein (E, western blotting normalized to
Vinculin) abundance in mouse RPE cells compared to
control siRNA transfection. n= 3, *p<0.05 by Student t-test.
(F) pAlu does not induce RPE degeneration in Myd88+1heterozygous (het) mice. (G) Western blot of Alu RNA
induced phosphorylation of IRAKl and IRAK4 in human
RPE cells. Image representative of 3 experiments. (H) pAlu
reduces cell viability of wild-type but not Mydss-1- mouse
RPE cells. (I) Loss of human RPE cell viability induced by
pAlu is rescued by MyD88i. (J) Subretinal injection of
AAVl-BESTl-Cre, but not AAVl-BESTl-GFP, protected
Myd8s17f mice from pAlu-induced RPE degeneration. (K)
pAlu transfection induces IL-18 secretion from human RPE
cells as assessed by ELISA. IL-1� secretion is barely
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detectable. n=3, *p<0.05 by Student t-test. (L) Intravitreous
administration of recombinant IL-18 induces RPE degen
eration in wild-type mice but not in Mydss-1- mice. (M and
N) pAlu-induced RPE degeneration in wild-type mice is not
rescued by intravitreous administration of IL-1 � neutralizing antibody (M) but is rescued by IL-18 neutralizing
antibody (N). Representative images shown. n=S-12. Fun
dus photographs, top row; Z0-1 stained (red) flat mounts,
bottom row. Degeneration outlined by blue arrowheads.
Scale bars, 20 µm (A-C, F, J, L-N). n= 3, *p<0.05 by Student
t-test. Error bars represent the SEM of samples within a
group (D, E, H, I, K).
FIG. 4. Alu RNA induces RPE degeneration via MyD88,
not TRIP or IFNy. (A) Subretinal administration of pAlu
induces RPE degeneration in Ticam1-1- mice. (B) Alu RNA
does not induce RPE degeneration in Mydss-1- mice. (C)
Subretinal administration ofa different Alu expression plas
mid (pAlu(2)) also induces RPE degeneration in wild-type
but not Mydss-1- mice. (D) Alu RNA does not induce RPE
degeneration in Myd881+1- heterozygous (het) mice. (E)
MyD88 inhibitory peptide reduces Alu RNA-induced phos
phorylation ofIRAKl/4, normalized to Vinculin expression.
(F) Subretinal injection of AAVl-BESTl-Cre, but not
AAVl-BESTl-GFP, protects Myd8st7f mice from Alu RNA
induced RPE degeneration. (G) pAlu and Alu RNA induces
RPE degeneration in wild-type mice receiving Mydss-1bone marrow (Mydss-1--wild-type) but did not do so in
Mydss-1- mice receiving wild-type bone marrow (wild
type-Mydss-1-). (H-K) Subretinal administration ofpAlu
induces RPE degeneration in Ifng-1- (H), Ifngrl-/- (I), and
Illrl-1+ mice (J) but not in Il18rl_1_ mice (K). pNull admin
istration does not induce RPE degeneration in any strain of
mice. Degeneration outlined by blue arrowheads. Fundus
photographs, top rows; Z0-1 stained (red) RPE flat mounts,
bottom rows. n=S (A-D, F-K).
FIG. 5. Alu RNA induces RPE degeneration via NLRP3
inflammasome. (A) Western blot of Caspase-1 activation
(p20 subunit) by Alu RNA in human RPE cells. (B) Western
blot ofpAlu-induced IL-18 maturation in RPE cell lysates in
wild-type mice impaired by intravitreous Caspase-1 peptide
inhibitor. (C) Intravitreous Caspase-1 peptide inhibitor pro
tects wild-type mice from pAlu-induced RPE degeneration.
(D) pAlu does not induce RPE degeneration in Casp1-1mice. (E) pAlu does not induce cytotoxicity in Casp1-1mouse RPE cells. (F) Alu RNA and LPS+ATP induce
formation of PYCARD clusters in human RPE cells trans
fected with GFP-PYCARD. See also FIG. 6E. (G and H)
pAlu does not induce RPE degeneration in Nlrp 3_1_ (G) or
Pycard-1- (H) mice. (I) Nlrp 3_1_ and Pycard-1- mouse RPE
cells are protected against pAlu-induced loss of cell viability. (J) siRNAs targeting NLRP3 or PYCARD rescued
human RPE cells from pAlu-induced cytotoxicity, compared
to control siRNA. n=3-4, *p<0.05 by Student t-test (A, B, E,
F, I, J). Images representative of 3 experiments. Densitom
etry values normalized to Vinculin are shown in parentheses
(A, B). Fundus photographs, top row; Z0-1 stained (red) flat
mounts, bottom row. Degeneration outlined by blue arrow
heads. n=S-12. Scale bars, 20 µm (C, D, G, H). Represen
tative images shown.
FIG. 6. Alu RNA induces RPE degeneration via NLRP3
inflammasome activation, Related to FIG. 7 (A)Alu RNA or
LPS+ATP induce activation of Caspase-1 in human RPE
cells as assessed by increased cleavage of Caspalux®l
(green, left panel), a fluorescent-linked peptide substrate as
compared to mock treatment. Fluorescence quantification
shown in right panel. (B) Western blot ofAlu RNA-induced
Caspase-1 activation (p20 subunit) in THP-1 and HeLa cells,

6

5

10

15

20

25

30

35

40

45

50

55

60

65

normalized to Vinculin expression. (C) Caspase-1 inhibitor
peptide blocks Alu RNA-induced substrate cleavage in
human RPE cells. n=3. (D) Subretinal injection ofAlu RNA
does not induce RPE degeneration in Casp1-1- mice. (E) Alu
RNA or LPS+ATP induce the appearance of a brightly
fluorescent cluster of GFP-PYCARD visible in the cytoplasm of human RPE cells. Area in insets shown in higher
magnification. Images representative of 3 experiments. (F
and G) Subretinal injection of Alu RNA does not induce
RPE degeneration in Nlrp 3_1_ (F) or Pycard-1- (G) mice. (H)
The abundance ofNLRP3 in HEK293 cells transfected with
an NLRP3 expression vector and of PYCARD in human
RPE cells is reduced by transfection of siRNAs targeting
these genes, compared to control (Ctr!) siRNAs. n=3,
*p<0.05 compared to Ctr! siRNAs by Student t-test. (I) Alu
RNA-induced Caspase-1 activation (p20 subunit) in human
RPE cells is unaffected by MyD88 inhibitory peptide, nor
malized to Vinculin expression. (J) MyD88 inhibitory pep
tide does not reduce Alu RNA-induced cleavage activity of
Caspase-1 in human RPE cells (top panel). Fluorescence
quantification (bottom panel). (K) Caspase-1 activation (p20
subunit) in RPE cell lysates of wild-type mice treated with
subretinal pAlu administration is unimpaired by intravitre
ous administration ofanti-IL-18 neutralizing antibodies. (L)
Alu RNA-induced phosphorylation ofIRAKl/4 is reduced
by Caspase-1 inhibitory peptide in human RPE cells, normalized to Vinculin expression. Vehicle control injections
also do not damage the RPE. Fundus photographs, top rows;
Z0-1 stained (red) RPE flat mounts, bottom rows. n=S (D,
F, G). Images representative of3 experiments (A, B, I, J-L).
FIG. 7. Priming and activation of NLRP3. (A) pAlu
induces NLRP3 and IL18 mRNAs in both wild-type and
Mydss-1- mouse RPE cells. (B) pAlu induces generation of
reactive oxygen species (ROS) in human RPE cells as
monitored with the fluorescent probe H2DCFDA (A.U,
arbitrary units). (C) The ROS inhibitor APDC blocks pAlu
induced NLRP3 and ILi 8 mRNAs in human RPE cells. (D)
Intravitreous administration of APDC protects wild-type
mice from pAlu-induced RPE degeneration. (E) pAlu does
not induce RPE degeneration in P2rx1-1- mice. (F) Intrav
itreous administration of P2X7 receptor antagonist protects
wild-type mice from pAlu-induced RPE degeneration. (G)
Intravitreous administration of glyburide, but not glipizide,
protects wild-type mice from pAlu-induced RPE degenera
tion. n=3-4, *p<0.05 by Student t-test (A-C). Representative
images shown. n= S-12. Fundus photographs, top row; Z0-1
stained (red) flat mounts, bottom row. Degeneration outlined
by blue arrowheads. Scale bars, 20 µm (D-G).
FIG. 8. IL-18 and MyD88 induce RPE degeneration via
Caspase-3. (A and B) Glycine inhibits human RPE cell death
induced by LPS+ATP (A) but not by pAlu (B). (C) Intrav
itreous administration of recombinant IL-18 induces RPE
degeneration in Caspi -I- mice. (D) IL-18-induced activation
of Caspase-3 in RPE cell lysates of wild-type mice. (E)
IL-18-induced RPE degeneration in wild-type mice is inhib
ited by intravitreous administration of Caspase-3 inhibitor.
(F) Intravitreous administration of MyD88 inhibitory pep
tide inhibits pAlu-induced cleavage ofCaspase-3 in the RPE
ofwild-type mice. n= 3-4 (A, B, D, F), *p<0.05 by Student
t-test. Representative images shown. n=S-12. Fundus pho
tographs, top row; Z0-1 stained (red) flat mounts, bottom
row. Degeneration outlined by blue arrowheads. Scale bars,
20 µm (C, E).
FIG. 9. DICER! loss induces cell death via inflam
masome. (A) Western blot ofAlu RNA-induced Caspase-1
cleavage (p20) inhibited by DICER! overexpression in
human RPE cells. (B and C) DICER! overexpression
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reduces Alu RNA-induced Caspase-1 activation in human
RPE cells (measured by cleavage (B left panel, green) of
Caspalux®l fluorescent substrate). Fluorescence quantifica
tion shown in right panel. (C) Western blot of increased
Caspase-1 activation l (p20 subunit) in RPE cell lysates of
BESTl-Cre;
Dicer]ff mice compared to BESTl-Cre or
l
Dicerlff mice. (D) Western blot of increased Caspase-1
activation (p20 subunit)
and IL-18 maturation in RPE cell
l
lysates of Dicer]ff mice treated with subretinal injection of
AAVl-BESTl-Cre. (E and F) RPE degeneration induced
by
l
subretinal injection of AAVl-BESTl-Cre in Dicer]ffmice is
rescued by intravitreous delivery of peptide inhibitors of
either Caspase-1 (E) or MyD88 (F). (G) MyD88 inhibitor
rescues loss of human RPE cell viability induced by
DICER! antisense (AS) treatment. (H) DICER! antisense
(AS) treatment of human RPE cells reduces DICER! level
and increases abundance of phosphorylation of IRAKl and
IRAK4, normalized to Vinculin expression. l (I) MyD88
inhibitor rescues loss of cell viability in Dicer]ffmouse RPE
cells treated with adenoviral vector coding for Cre recom
binase (Ad-Cre). (J) Ad-Cre
induced global miRNA expres
l
sion deficits in Dicer]ff mouse RPE cells compared to
Ad-Null. No significant difference in miRNA abundance
between MyD88 inhibitor and control peptide-treated Dicer'
depleted cells. n=3 (A, B, F-H). Densitometry values nor
malized to Vinculin are shown in parentheses (A, C). Degen
eration outlined by blue arrowheads. n=S (E, F). *p<0.05 by
Student t-test (G, I). Images representative of 3 experiments
(A, B, C, D, H).
FIG. 10. DICER! is a negative regulator of Caspase-1
activation by Alu RNA, Related to FIG. 9 (A) Knockdown
of DICER! by antisense oligonucleotides (AS) in human
RPE cells increases cleavage activity of Caspase-1, as
monitored by Caspalux, a fluorescent (green in overlay)
reporter of substrate cleavage compared to control AS
treatment. (B) Inhibition of Alu RNA by AS treatment
reduces Caspalux fluorescence in human RPE cells treated
with DICER! AS. Mean values of Caspalux fluorescence
shown in parentheses. Images representative of 3 experi
ments.
FIG. 11. NLRP3 Inflammasome and MyD88 activation in
human GA. (A) NLRP3 and IL18 abundance was signifi
cantly elevated in macular GA RPE (n= 13) compared to
normal age-matched controls (n=12). *p<0.05 by Mami
Whitney U-test. There was no significant difference between
groups (p=0.32 by Marni-Whitney U-test) in ILlB abun
dance. (B-D) Increased immunolocalization of NLRP3 (B),
PYCARD (C) and Caspase-1 (D) in macular GA RPE
compared to age-matched normal controls. Specificity of
staining confirmed by absence of reaction production with
isotype control antibody in GA eye sections. Scale bar, 20
µm. (E) Western blots of macular RPE lysates from indi
vidual human donor eyes show that abundance of NLRP3,
PYCARD, and phosphorylated IRAKl/4 (which are acti
vated by MyD88 signaling), normalized to the levels of the
housekeeping protein Vinculin, is reduced in geographic
atrophy (GA) compared to age-matched normal controls.
Representative images shown. n=6 (B-E).
FIG. 12, Schematic representation of proposed model of
NLRP3 inflammasome activation by DICER! deficit-in
duced Alu RNA that leads to RPE degeneration and geo
graphic atrophy. Alu RNA induces priming of NLRP3 and
ILi 8 mRNAs via generation of reactive oxygen species
(ROS). Alu RNA activates the NLRP3 inflammasome via
P2X7 activation. This triggers cleavage of pro-IL-18 by
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activated Caspase-1 to mature IL-18. IL-18 signals via
MyD88 to phosphorylate IRAKl and IRAK4, which leads
to activation of Caspase-3.
FIG. 13 includes a series of images showing stained flat
mounts following intravitreous administration of N-(2-Mor
pholinylethyl)-2-(3-nitrobenzoylamido)-benzimidazole, an
IRAKl/4 inhibitor, in wild-type mice, showing that
IRAKl/4 inhibitors protects wild-type mice from Alu RNA
induced RPE degeneration in a dose-dependent mamier.
FIG. 14 is a bar graph presenting viability of human RPE
cells, and showing that N-(2-Morpholinylethyl)-2-(3-ni
trobenzoylamido)-benzimidazole, an IRAKl/4 inhibitor
(100 µM), protects human RPE cells from pAlu-induced
cytotoxicity.
FIG. 15 is a bar graph presenting viability of human RPE
cells, and showing that N-(2-Morpholinylethyl)-2-(3-ni
trobenzoylamido)-benzimidazole, an IRAKl/4 inhibitor
(100 µM), protects human RPE cells from Alu Alu-induced
cytotoxicity.
FIG. 16 is a bar graph showing that MyDss-1- mice have
reduced laser-induced choroidal neovascularization as com
pared to wild-type mice.
FIG. 17 is a bar graph showing that intravitreous injection
of a peptide MyD88 inhibitor reduced laser-induced chor
oidal neovascularization in wild-type mice compared to a
control peptide inhibitor.
FIG. 18 is a bar graph showing that intravitreous injection
of an siRNA targeting MyD88 (2 µg) reduced laser-induced
choroidal neovascularization in wild-type mice at least as
well as a neutralizing anti-mouse VEGF antibody, compared
to a control sirRNA.
DESCRIPTION OF EXEMPLARY
EMBODIMENTS
The details of one or more embodiments of the presently
disclosed subject matter are set forth in this document.
Modifications to embodiments described in this document,
and other embodiments, will be evident to those of ordinary
skill in the art after a study of the information provided in
this document. The information provided in this document,
and particularly the specific details of the described exem
plary embodiments, is provided primarily for clearness of
understanding and no unnecessary limitations are to be
understood therefrom. In case of conflict, the specification of
this document, including definitions, will control.
The presently-disclosed subject matter includes methods
for inhibiting P2X7 activation and therapeutic and protective
uses thereof. Also provided are method for inhibiting
IRAKl and therapeutic and protective uses thereof. Also
provided are methods for inhibiting IRAK4 and therapeutic
and protective uses thereof. Also provided are methods for
identifying inhibitors.
In some embodiments, the presently-disclosed subject
matter includes a method of protecting a cell, which involves
inhibiting one or more of P2X7 activation associated with or
in the cell, inhibiting IRAKl associated with or in the cell;
or inhibiting IRAK4 associated with or in the cell. The cell
being protected can be, for example, an RPE cell, a retinal
photoreceptor, or a choroidal cell. In some embodiments, the
cell is in a subject. In some embodiments, the cell is an RPE
cell. In some embodiments, the method includes identifying
a subject for which protection of an RPE cell is desired. In
some embodiments of the method, the cell is an RPE cell of
a subject having age-related macular degeneration.
As will be recognized by one or ordinary skill in the art,
the term "protecting" or "protection" when used with ref-
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erence to a cell or group of cells does not refer to an ability
to complete eliminate all instances of cell death. Rather, the
skilled artisan will understand that the term "protecting"
refers to a reduction in cytotoxicity for a cell or group of
cells, or to a reduction in the likelihood of cell death for a
cell or group of cells, e.g., Alu-RNA-induced cytotoxicity or
cell death. Such reduction can be a reduction by at least
about 50%, at least about 75%, at least about 90%, or at least
about 95% of the cytotoxicity/cell death of a cellular popu
lation. Such reduction can be determined relative to a
control, e.g., in the absence of P2X7 activation inhibitor,
IRAK-1 inhibitor, and/or IRAK-4 inhibitor.
An inhibitor as described herein can be a polypeptide
inhibitor (including oligonucleotide inhibitor), a small mol
ecule inhibitor, or an siRNA inhibitor. It is noted that, the
terms "inhibit", "inhibitor", or "inhibiting" are not meant to
require complete inhibition, but refers to a reduction in
signaling. Such reduction can be a reduction by at least
about 50%, at least about 75%, at least about 90%, or at least
about 95% of the signaling in the absence of the inhibitory
effect, e.g., in the absence of a compound that is an inhibitor
of the signaling.
In some embodiments of the presently-disclosed subject
matter, a method of protecting a cell can include inhibiting
of P2X7 activation associated with or in the cell of the
subject. In some embodiments, the method further includes
identifying a subject in need of treatment for a condition of
interest. In some embodiments, inhibiting P2X7 activation
includes contacting the cell with a P2X7 activation inhibitor.
In some embodiments, contacting the cell with the inhibitor
comprises administering the inhibitor to a subject. Such
inhibitors can be administered, for example, by topical,
intravitreous, subretinal, peribulbar, suprachoroidal, intraca
psular, intravenous, intramuscular, or subcutaneous admin
istration, or by inhalational of the inhibitor.
Examples of appropriate P2X7 activation inhibitors
include, but are not limited to a P2X7 receptor antagonist
(e.g., A438079), an inhibitor of the activation of the P2X7
receptor, or an inhibitor of the expression of P2X7 (includ
ing, for example, inhibition of transcription of the P2RX7
gene, and inhibition of translation of a product of the P2RX7
gene, including by use of RNA interference technologies).
Examples of inhibitors include, polypeptide inhibitors
(which include oligonucleotide inhibitors), small molecule
inhibitors, and siRNA inhibitors.
In some embodiments of the presently-disclosed subject
matter, a method of protecting a cell can include inhibiting
IRAKl and/or IRAK 4 associated with or in the cell of the
subject. In some embodiments, the method further includes
identifying a subject in need of treatment for a condition of
interest. In some embodiments, inhibiting IRAKl and/or
IRAK 4 includes contacting the cell with a IRAKl and/or
IRAK 4 inhibitor. In some embodiments, contacting the cell
with the inhibitor comprises administering the inhibitor to a
subject. Such inhibitors can be administered, for example,
by topical, intravitreous, subretinal, peribulbar, suprachor
oidal, intracapsular, intravenous, intramuscular, or subcuta
neous administration, or by inhalational of the inhibitor.
Examples of appropriate IRAKl and/or IRAK 4 inhibitors
include, an antagonist, such as a small molecule antagonist,
or an inhibitor of the expression of IRAKl, and/or IRAK4
(including, for example, inhibition of transcription and inhi
bition of translation, including by use of RNA interference
technologies). Examples of inhibitors include, polypeptide
inhibitors (which include oligonucleotide inhibitors), small
molecule inhibitors, and siRNA inhibitors. Specific
examples of inhibitors that can be used in accordance with
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the presently-disclosed subject matter include but are not
limited
to
N-(2-Morpholinylethyl)-2-(3-nitrobenzoy
lamido )-benzimidazole, and other examples are described,
for example, in Buckley, G. M, et al., (2008) "IRAK-4
inhibitors. Part III: A series of imidazo[l,2-a]pyridines"
Bioorganic & Medicinal Chemistry Letters, 18:656-3660,
and other known IRAK inhibitors, including those being
developed by Merck (e.g., eshop.emdchemicals.com) and
Ligand Pharmaceuticals (e.g., www.ligand.com/irak4-inhibitor).
The methods as described herein can further include
inhibiting MyD88 associated with or in a cell of the subject;
inhibiting IL-18 associated with or in a cell of the subject;
inhibiting an inflammasome associated with or in a cell of
the subject; increasing levels of a DICER polypeptide asso
ciated with or in a cell of the subject; and/or inhibiting
AluRNA associated with or in a cell of the subject. Relevant
information and details regarding such additional steps of
embodiments of the presently-disclosed subject matter can
be found, for example, in U.S. Provisional Patent Applica
tion No. 61/543,038; U.S. Provisional Patent Application
No. 61/508,867; and International Patent Application No.
PCT/USll/38753, each of which is incorporated herein by
reference.
In some embodiments, the method of protecting a cell as
described herein can be useful for the treatment of a con
dition of interest, for example, a condition selected from:
Geographic atrophy; Macular degeneration; Alzheimer dis
ease; Cryopyrinopathies; Inflammatory Bowel Disease;
Keratitis; Gout; Acne vulgaris; Crohn's disease; Ulcerative
colitis; Irritable bowel syndrome; Type I diabetes; Type 2
diabetes; Insulin resistance; Obesity; Hemolytic-Uremic
Syndrome; Polyoma virus infection; Immune complex renal
disease; Acute tubular injury; Lupus nephritis; Familial cold
autoinflammatory syndrome; Muckle-Wells syndrome and
neonatal onset multisystem inflammatory disease; Chronic
infantile neurologic cutaneous and articular autoinflamma
tory diseases, Renal ischemia-perfusion injury; Glomerulonephritis; Cryoglobulinemia; Systemic vasculitides; IgA
nephropathy Atherosclerosis; HIV/AIDS; Malaria; Hel
minth parasites; Sepsis and septic shock; Allergic asthma;
Hay fever; Chronic obstructive pulmonary disease; Drug
induced lung inflammation; Contact dermatitis; Leprosy;
Burkholderia cenocepacia infection; Respiratory syncitial
virus infection; Psoriasis; Systemic lupus erythematosus;
Scleroderma; Reactive arthritis; Cystic fibrosis, Syphilis,
Sjiigren's syndrome; Rheumatoid arthritis; Inflammatory
joint disease; Non-alcoholic fatty liver disease; Cardiac
surgery (peri-/post-operative inflanimation); Acute and
chronic organ transplant rejection; Acute and chronic bone
marrow transplant rejection; and Tumor angiogenesis. In
some embodiments, the condition of interest is geographic
atrophy and the cell is an RPE cell. In this regard, a subject
having age-related macular degeneration can be treated
using methods and compositions as disclosed herein. It is
noted that macular degeneration refers to both a dry form of
macular degeneration (e.g., geographic atrophy/retinal
degeneration), as well as a wet form of macular degeneration
(e.g., angiogenesis/blood vessel growth). In this regard,
inhibitors as disclosed herein can be useful for treating all
forms of macular degeneration. By way of specific example,
a MyD88 inhibitor can be used to treat various forms of
macular degeneration, and is specifically contemplated for
inhibition of choroidal neovascularization.
As used herein, the terms treatment or treating relate to
any treatment of a condition of interest, including but not
limited to prophylactic treatment and therapeutic treatment.
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As such, the terms treatment or treating include, but are not
limited to: preventing a condition of interest or the devel
opment of a condition of interest; inhibiting the progression
of a condition of interest; arresting or preventing the devel
opment of a condition of interest; reducing the severity of a
condition of interest; ameliorating or relieving symptoms
associated with a condition of interest; and causing a regres
sion of the condition of interest or one or more of the
symptoms associated with the condition of interest.
As used herein, the term "subject" refers to a target of
treatment. The subject of the herein disclosed methods can
be a vertebrate, such as a mammal, a fish, a bird, a reptile,
or an amphibian. Thus, the subject of the herein disclosed
methods can be a human or non-human. Thus, veterinary
therapeutic uses are provided in accordance with the pres
ently disclosed subject matter.
The terms "polypeptide", "protein", and "peptide", which
are used interchangeably herein, refer to a polymer of the 20
protein amino acids, or amino acid analogs, regardless of its
size. The terms "polypeptide fragment" or "fragment", when
used in reference to a reference polypeptide, refers to a
polypeptide in which amino acid residues are deleted as
compared to the reference polypeptide itself, but where the
remaining amino acid sequence is usually identical to the
corresponding positions in the reference polypeptide. Such
deletions can occur at the amino-terminus or carboxy
terminus of the reference polypeptide, from internal portions
of the reference polypeptide, or a combination thereof. A
fragment can also be a "functional fragment," in which case
the fragment retains some or all of the activity of the
reference polypeptide as described herein.
The terms "modified amino acid", "modified polypep
tide", and "variant" refer to an amino acid sequence that is
different from the reference polypeptide by one or more
amino acids, e.g., one or more amino acid substitutions. A
variant of a reference polypeptide also refers to a variant of
a fragment of the reference polypeptide, for example, a
fragment wherein one or more amino acid substitutions have
been made relative to the reference polypeptide. A variant
can also be a "functional variant," in which the variant
retains some or all of the activity of the reference protein as
described herein. The term functional variant includes a
functional variant of a functional fragment of a reference
polypeptide.
The presently-disclosed subject matter further includes a
kit, useful for practicing the methods as disclosed herein. In
some embodiments, the kit can include a P2X7 activation
inhibitor, packaged together with an IRAKl and/or IRAK4
inhibitor. In some embodiments, the kit can also include an
IL-18 inhibitor, an inflammasome inhibitor, a DICER polypeptide, and an AluRNA inhibitor.
The presently-disclosed subject matter also includes a
method for identifying an IRAKl and/or IRAK 4 inhibitor,
including providing a cultured cell wherein phosphorylated
IRAKl and/or IRAK4 is upregulated; contacting the cell
with a candidate compound; and determining whether the
candidate compound results in a change in the IRAKl
and/or IRAK4. The IRAKl and/or IRAK4 can be upregu
lated in the cell, for example, by stimulating the cells with
a MyD88 activator (e.g., Alu-RNA, LPS) and measuring
phosphorylation (activation) of IRAKl and/or IRAK4 by
Western blotting. The change in the IRAKl and/or IRAK4
can monitored, for example, by measuring cell viability, or
measuring the expression of a gene known to be induced by
IRAK 1 and/or IRAK 4 signaling.
In certain instances, nucleotides and polypeptides dis
closed herein are included in publicly-available databases,
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such as GENBANK® and SWISSPROT. Information
including sequences and other information related to such
nucleotides and polypeptides included in such publicly
available databases are expressly incorporated by reference.
Unless otherwise indicated or apparent the references to
such publicly-available databases are references to the most
recent version of the database as of the filing date of this
Application.
While the terms used herein are believed to be well
understood by one of ordinary skill in the art, definitions are
set forth to facilitate explanation of the presently-disclosed
subject matter.
Unless defined otherwise, all technical and scientific
terms used herein have the same meaning as commonly
understood by one of ordinary skill in the art to which the
presently-disclosed subject matter belongs. Although any
methods, devices, and materials similar or equivalent to
those described herein can be used in the practice or testing
of the presently-disclosed subject matter, representative
methods, devices, and materials are now described.
Following long-standing patent law convention, the terms
"a", "an", and "the" refer to "one or more" when used in this
application, including the claims. Thus, for example, refer
ence to "a cell" includes a plurality of such cells, and so
forth.
Unless otherwise indicated, all numbers expressing quan
tities of ingredients, properties such as reaction conditions,
and so forth used in the specification and claims are to be
understood as being modified in all instances by the term
"about". Accordingly, unless indicated to the contrary, the
numerical parameters set forth in this specification and
claims are approximations that can vary depending upon the
desired properties sought to be obtained by the presently
disclosed subject matter.
As used herein, the term "about," when referring to a
value or to an amount of mass, weight, time, volume,
concentration or percentage is meant to encompass varia
tions of in some embodiments ±20%, in some embodiments
±10%, in some embodiments ±5%, in some embodiments
±1%, in some embodiments ±0.5%, and in some embodi
ments ±0.1% from the specified amount, as such variations
are appropriate to perform the disclosed method.
As used herein, ranges can be expressed as from "about"
one particular value, and/or to "about" another particular
value. It is also understood that there are a number of values
disclosed herein, and that each value is also herein disclosed
as "about" that particular value in addition to the value itself.
For example, if the value "10" is disclosed, then "about 10"
is also disclosed. It is also understood that each unit between
two particular units are also disclosed. For example, if 10
and 15 are disclosed, then 11, 12, 13, and 14 are also
disclosed.
The presently-disclosed subject matter is further illus
trated by the following specific but non-limiting examples.
The following examples may include compilations of data
that are representative of data gathered at various times
during the course of development and experimentation
related to the present invention.
EXAMPLES
Example 1

65

Subretinal Injection and Imaging.
Subretinal injections (1 µL) in mice were performed using
a Pico-Injector (PLI-100, Harvard Apparatus). In vivo trans
fection of plasmids was achieved using 10% Neuroporter
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(Genlantis). Fundus imaging was performed on a TRC-50
IX camera (Topcon) linked to a digital imaging system
(Sony). Immunolabeling of RPE flat mounts was performed
using antibodies against human zonula occludens-1 (Invit
rogen).
Cell Viability.
Cell viability measurements were performed using the
CellTiter 96 AQueous One Solution Cell Proliferation Assay
(Promega) in according to the manufacturer's instructions.
mRNA Abundance.
Transcript abundance was quantified by real-time RT
PCR using an Applied Biosystems 7900 HT Fast Real-Time
PCR system using the 2-Mct method.
Protein Abundance and Activity.
Protein abundance was assessed by Western blot analysis
using primary antibodies recognizing Caspase-1 (1:500;
Invitrogen), pIRAKl (1:500; Thermo Scientific), pIRAK4
(1:500, Abbomax, Inc), PYCARD (1:200, Santa Cruz Bio
technology), NLRP3 (1:500, Enzo Life Sciences) and Vin
culin (1:1,000; Sigma-Aldrich). Caspase-1 activity was
visualized using Caspaluxl E1D2 (Oncoimmunin) reagent
according to the manufacturer's instructions.
Mice.
All animal experiments were approved by institutional
review committees and in accordance with the Association
for Research in Vision and Ophthalmology Statement for the
Use of Animals in Ophthalmic and Visual Research. Wild
type C57BL/6J, Tlr3-1-, Tlr4- 1- (C57BL/10ScNJ), Trif-1(TicamlLps2) Ifng_;_ Ifngr1-1- Illrl-/- Ill8rl-/- P2rx7_;_
Myd8st7--'; a�d Dice;]flf mice' were p�chased 'from Th�
Jackson Laboratory. Casp1-1-, Nlrp3-1-, and Pycard-1- mice
have been previously described (Kanneganti et al., 2006).
Unc93bl mutant mice were generously provided by B. A.
Beutler via K. Fitzgerald. Myd88_1_ and Tlr7_1_ mice were
generously provided by S. Akira via T. Hawn and D. T.
Golenbock. Mda5_1_ mice were generously provided by M.
Colonna. Prkr-1- mice were generously provided by B. R.
Williams and R. L. Silverman. Mavs-1- mice were gener
ously provided by Z. Chen via K. Fitzgerald. For all pro
cedures, anesthesia was achieved by intraperitoneal injec
tion of 100 mg/kg ketamine hydrochloride (Ft. Dodge
Animal Health) and 10 mg/kg xylazine (Phoenix Scientific),
and pupils were dilated with topical 1% tropicamide (Alcon
Laboratories).
Fundus Photography.
Retinal photographs of dilated mouse eyes were taken
with a TRC-50 IX camera (Topcon) linked to a digital
imaging system (Sony).
Human Tissue.
Donor eyes or ocular tissues from patients with geo
graphic atrophy due to AMD or age-matched patients with
out AMD were obtained from various eye banks. These
diagnoses were confirmed by dilated ophthalmic examina
tion prior to acquisition of the tissues or eyes or upon
examination of the eye globes post mortem. The study
followed the guidelines of the Declaration of Helsinki.
Institutional review boards granted approval for allocation
and histological analysis of specimens.
Immunolabeling.
Human eyes fixed in 2-4% paraformaldehyde were pre
pared as eyecups, cryoprotected in 30% sucrose, embedded
in optimal cutting temperature compound (Tissue-Tek OCT;
Sakura Finetek), and cryosectioned into 10 µm sections.
Depigmentation was achieved using 0.25% potassium per
manganate and 0.1% oxalic acid. Immunohistochemical
staining was performed with the rabbit antibody against
NLRP3 (1:100, Si gma Aldrich) or rabbit antibody against
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Caspase-1 (prediluted, AbCam). Isotype IgG was substituted
for the primary antibody to assess the specificity of the
staining. Bound antibody was detected with biotin-conju
gated secondary antibodies, followed by incubation with
ABC reagent and visualized by Vector Blue (Vector Labo
ratories). Levamisole (Vector Laboratories) was used to
block endogenous alkaline phosphatase activity. Slides were
washed in PBS, counterstained with neutral red (Fisher
Scientific), rinsed with deionized water, air dried, and then
mounted in Vectamount (Vector Laboratories). Fluorescent
labeling of human tissue was performed with the rabbit
antibody against PYCARD (1:50, Clone N-15, Santa Cruz
Biotechnology). Immunolabeling was visualized by fluores
cently conjugated anti-rabbit secondary antibody (Invitrogen). Tissue autofluorescence was quenched by incubating
the sections in 0.3% Sudan black (Fisher Scientific). Sec
tions were mounted in Vectashield with DAPI (Vector Labo
ratories). Mouse RPE/choroid flat mounts were fixed with
4% paraformaldehyde or 100% methanol, stained with rabbit antibodies against human zonula occludens-1 (1:100,
Invitrogen) and visualized with Alexa594 (Invitrogen). All
images were obtained using the Leica SP-5 or Zeiss Axio
Observer Zl microscopes.
Subretinal Injection.
Subretinal injections (1 µL) in mice were performed using
a Pico-Injector (PLI-100, Harvard Apparatus). In vivo trans
fection of plasmids coding for two different Alu sequences
(pAlu) or empty control vector (pNull) (Bennett et al., 2008;
Kaneko et al., 2011; Shaikh et al., 1997) was achieved using
10% Neuroporter (Genlantis). AAVl-BESTl-Cre (Alexan
der and Hauswirth, 2008) or AAVl-BESTl-GFP were
injected at 1.0xl011 pfu/mL and in vitro transcribed Alu
RNA was injected at 0.3 mg/mL.
Drug Treatments.
siRNAs formulated in siRNA buffer (20 mM KCL, 0.2
mM MgC12 in HEPES buffer at pH 7.5; Dharmacon) or
phosphate buffered saline (PBS; Si gma-Aldrich); the TLR4
antagonist Ultra Pure Rhodobacter sphaeroides LPS (LPS
RS, InvivoGen), a peptide inhibitor of MyD88 homodimerization IMG-2005 (IMGENEX), control inhibitor (IM
GENEX), recombinant IL-18 (Medical & Biological
Laboratories), neutralizing rat antibodies against mouse
IL-1� (IMGENEX), neutralizing rat antibodies against
mouse IL-18 (Medical & Biological Laboratories), isotype
control IgGs (R&D Systems or eBioscience as appropriate),
Caspase-1 inhibitor Z-WEHD-FMK (R&D Systems), Cas
pase-3 inhibitor Z-DEV D-FMK (R&D Systems), Caspase
control inhibitor Z-FA-FMK (R&D Systems), (2R,4R)
APDC (Enzo Life Sciences), Glipizide (Sigma-Aldrich),
Glyburide (Sigma-Aldrich), and P2X7 receptor antagonist
A438079 (Tocris Bioscience) were dissolved in phosphate
buffered saline (PBS; Si gma-Aldrich) or dimethyl sulfoxide
(DMSO; Sigma-Aldrich), and injected into the vitreous
humor in a total volume of 1 µL with a 33-gauge Exmire
microsyringe (Ito Corporation). To assess the effect of
MyD88 blockade on pAlu-induced RPE degeneration, 1 µL
of cholesterol (chol) conjugated MyD88 siRNA (17+2 nt; 2
µg/µL) was intravitreously injected 1 day after pAlu injec
tion. As a control, Luc siRNA-chol (17+2 nt) was used with
identical dosages.
Bone Marrow Chimeras.
Bone marrow transplantation was used to create
Myd88-1- chimera mice wherein the genetic deficiency of
Myd88 was confined to either circulating cells (Myd88_1_
-WT) or nonhematopoietic tissue (WT-Myd88-1-).
Briefly, bone marrows were collected from femur and tibia
of congenic WT or Myd88_1_ donor mice by flushing with
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RPMI1640. After two washing steps, cells were resuspended
in RPMI1640. lxl0 7 cells in 150 µL of RPMI1640 were
injected into the tail vein of irradiated donor mice. Two
chimera groups were generated: WT----;,Myd88_1_ (WT cells
into Myd88-1- mice) and Myd88-1- -;,WT (Myd88-1- cells
into WT mice). 2 months after bone marrow transfer, mice
were injected subretinally with Alu RNA, vehicle, pA!u, or
pNull, and monitored for RPE degeneration 7 days later.
Real-Time PCR.
Total RNA was extracted from tissues or cells using Trizol
reagent (Invitrogen) according to manufacturer's recom
mendations, DNase treated and reverse transcribed (Quan
tiTect, Qiagen). The RT products (cDNA) were amplified by
real-time quantitative PCR (Applied Biosystems 7900 HT
Fast Real-Time PCR system) with Power SYBR green
Master Mix. Oligonucleotide primers specific for human
ILlB, human NLRP3, human 18S rRNA, mouse Myd88,
mouse Nlrp3, mouse 1118, and mouse 18S rRNA were used.
The QPCR cycling conditions were 50 ° C. for 2 min, 95 ° C.
for 10 min followed by 40 cycles of a two-step amplification
program (95 ° C. for 15 s and 58 ° C. for 1 min). At the end
of the amplification, melting curve analysis was applied
using the dissociation protocol from the Sequence Detection
system to exclude contamination with unspecific PCR prod
ucts. The PCR products were also confirmed by agarose gel
and showed only one specific band of the predicted size. For
negative controls, no RT products were used as templates in
the QPCR and verified by the absence of gel-detected bands.
Relative expressions of target genes were determined by the
2-,\.,\.ct method.
miRNA Quantification.
Total RNA containing miRNAs was polyadenylated and
reverse transcribed using universal primer using the All-In
One miRNA q-RT-PCR Detection Kit (GeneCopoeia)
according to the manufacturer's specifications using a universa! reverse primer in combination with forward primers
for: mouse miR-184; mouse miR-221/222; mouse miR320a; and mouse miR-484. miRNA levels were normalized
to levels of U6 snRNA using the 2-Mct method. Detection
was achieved by SYBR green qPCR with the following
conditions: 95 ° C. for 10 min followed by 40 cycles of 95 °
C. for 10 s, 60 ° C. for 20 s and 72 ° C. for 20 s. Amplicon
specificity was assessed by melt curve analysis and unique
bands by agarose gel electrophoresis.
Western Blotting.
Tissues or cells were homogenized in lysis buffer (10 mM
Tris base, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 1% Triton X-100, 0.5% NP-40, protease and phos
phatase inhibitor cocktail (Roche)). Protein concentrations
were determined using a Bradford assay kit (Bio-Rad) with
bovine serum albumin as a standard. Proteins (40-100 µg)
were run on NuPAGE Bis-Tris gels (Invitrogen) and trans
ferred to Immun-Blot PVDF membranes (Bio-Rad). Cells
were scraped in hot Laemmli buffer (62.5 mM Tris base, pH
6.8, 2% SDS, 5% 2-Mercaptoethanol, 10% Glycerol, 0.01%
Bromophenol Blue). Samples were boiled and run on 4-20%
NuPAGE Tris-Glycine gels (Invitrogen). The transferred
membranes were blocked for 1 h at RT and incubated with
antibodies against human Caspase-1 (1:500; Invitrogen),
mouse Caspasel (1:500; MBL), NLRP3 (1:1000; Enzo Life
Sciences), PYCARD (1:1000, RayBiotech), phospho
IRAKl (S376) (1:500, Thermo Scientific), phospho-IRAK4
(T345) (1:500, AbboMax), DICERl (1:2,000; Bethyl),
MyD88 (1:1,000; Cell Signaling), and mouse IL-18 (1:200;
MBL) at 4 ° C. overnight. Protein loading was assessed by
immunoblotting using an anti-Vinculin antibody (1:1,000;
Sigma-Aldrich). The secondary antibodies were used (1:5,
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000) for 1 h at RT. The signal was visualized by enhanced
chemiluminescence (ECL plus) and captured by Vision
WorksLS Image Acquisition and Analysis software (Version
6.7.2, UVP, LLC).
Cell Culture.
All cell cultures were maintained at 37 ° C. and 5% C02.
Primary mouse RPE cells were isolated as previously
described (Yang et al., 2009) and grown in Dulbecco Modi
fied Eagle Medium (DMEM) supplemented with 20% FBS
and standard antibiotics concentrations. Primary human
RPE cells were isolated as previously described (Yang et al.,
2008) and maintained in DMEM supplemented with 10%
FBS and antibiotics. HeLa cells were maintained in DMEM
supplemented with 20% FBS and standard antibiotics con
centrations. THP-1 cells were cultured in RPMI 1640
medium supplemented with 10% FBS and antibiotics.
In Vitro Transcription of Alu RNAs.
Two Alu RNAs were synthesized: a 281 nt Alu sequence
originating from the cDNA clone TS 103 (Shaikh et al.,
1997) and a 302 nt Alu sequence isolated from the RPE of
a human eye with geographic atrophy. Linearized plasmids
containing these Alu sequences with an adjacent 5' T7
promoter were subjected to AmpliScribe™ T7-Flash™
Transcription Kit (Epicentre) according to the manufactur
er's instructions. DNase-treated RNA was purified using
MEGAclear™ (Ambion), and integrity was monitored by
gel electrophoresis. This yields single stranded RNAs that
fold into a defined secondary structure identical to Pol III
derived transcripts. Where indicated, transcribed RNA was
dephosphorylated using calf intestine alkaline phosphatase
(Invitrogen) and repurified by Phenol:Chloroform:Isoamyl
alcohol precipitation.
Transient Transfection.
Human or mouse RPE cells were transfected with pUCl9,
pA!u, pCDNA3.1/Dicer-FLAG, pCDNA3.1, Alu RNA,
NLRP3 siRNA sense, PYCARD siRNA sense, MyD88
siRNA sense, DICERl antisense oligonucleotide (AS), con
trol (for DICERl) AS, Alu AS, and control (for Alu) AS
using Lipofectamine 2000 (Invitrogen) according to the
manufacturer's instructions.
Adenoviral Infection.
Cells were plated at density of 15xl0 3/cm 2 and after 16 h,
at approximately 50% confluence, were infected with AdCre
or AdNull (Vector Laboratories) with a multiplicity of
infection of 1,000.
Cell Viability.
MTS assays were performed using the Cell Titer 96 AQue
ous One Solution Cell Proliferation Assay (Promega)
according to the manufacturer's instructions. For examining
the cytoprotective effect of glycine in Alu RNA induced cell
death, human RPE cells were transfected with pNull/pA!u.
At 6 h post-transfection the cells were incubated with
complete media containing glycine (5 mM) or vehicle, and
cell viability was assessed after 24 h. Similarly, human RPE
cells primed with LPS (5 µg/ml for 6 h) were treated with
ATP (25 µM) in the presence of glycine containing media (5
mM). 30 min post ATP cell viability was assessed as
described above.
Caspase-1 Activity.
Caspase-1 activity was visualized by incubating cells with
CaspaluxlEl D2 reagent (Oncoimmunin) according to the
manufacturer's instructions. Caspalux1E1D2 signal was
quantified reading the fluorescence (excitation 552 nm,
emission 580 nm) using a Synergy 4 reader (Biotek). Quan
tification of fluorescence from images was performed by
converting images into grayscale in Adobe Photoshop CS5,
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and measuring the integrated density of black and white
images using ImageJ software (NIH) (Bogdanovich et al.,
2008).
Caspase-3 Activity.
The caspase-3 activity was measured using Caspase-3
Fluorimetric Assay (R&D Systems) according to the manu
facturer's instruction.
ROS Activation.
Intracellular ROS was assessed using the ROS-specific
probe 2'7'-dichlorodihydrofluorescin diacetate (H2DCFDA,
BioChemica, Fluka). Sub-confluent human RPE cells were
transfected with pNull and pAlu. After 24 h cells were
loaded for 10 min with 10 µM H2DCFDA and washed twice
with PBS. Fluorescence was recorded in 96-well plate using
with a Synergy 4 reader (Biotek) using a FITC filter (exci
tation 485 nm, emission 538 nm).
ELISA.
Secreted cytokine content in conditioned cell culture
media was analyzed using the Human IL-1� and IL-18
ELISA Kits (R&D) according to the manufacturer's instruc
tions.
TLR Screen.
A custom TLR ligand screen was performed by Invivo
Gen using HEK293 cells over-expressing individual TLR
family members coupled with an AP-1/NF-KB reporter
system. Cells were stimulated with each of two Alu RNAs
synthesized by in vitro transcription, or a TLR-specific
positive control ligand.
Statistical Analysis.
Results are expressed as mean±SEM, with p values <0.05
considered statistically significant. Differences between
groups were compared by using Mann-Whitney U test or
Student t-test, as appropriate, and 2-tailed p values are
reported.
Results
Alu RNA does not Activate a Variety of TLRs or RNA
Sensors.
Alu RNA has single-stranded (ss) RNA and double
stranded (ds) RNA motifs (Sinnett et al., 1991). Therefore,
whether Alu RNA induced RPE degeneration in mice defi
cient in toll-like receptor-3 (TLR3), a dsRNA sensor (Alexo
poulou et al., 2001), or in TLR7, a ssRNA sensor (Diebold
et al., 2004; Heil et al., 2004) was tested. Subretinal admin
istration of a plasmid coding for Alu RNA (pAlu) induced
RPE degeneration in Tlr3_1_ and Tlr7_1_ mice just as in
wild-type mice (FIGS. lA-C). It has been shown that
21-nucleotide or longer fully complementary siRNAs can
activate TLR3 on RPE cells (Kleinman et al., 2011). The
lack of TLR3 activation by Alu RNA can be attributed to its
complex structure containing multiple hairpins and bulges
that might preclude it from binding TLR3. Neither 7SL
RNA, the evolutionary precursor of Alu RNA that also has
ssRNA and dsRNA motifs, nor p7SL induced RPE degen
eration in wild-type mice (FIGS. 2A and 28), suggesting
that the cytotoxicity of Alu RNA might be due to as yet
unclear structural features. pAlu induced RPE degeneration
in Unc93bl mutant mice (FIG. lD), which are devoid of
signaling from TLR3, TLR7, and TLR9 (Tabeta et al., 2006),
indicating that these nucleic acid sensing TLRs are not
activated by Alu RNA redundantly. pAlu administration also
induced RPE degeneration in Tlr4_1_ mice (FIG. lE). Cor
roborating these data, the TLR4 antagonist Rhodobacter
sphaeroides LPS (Qureshi et al., 1991) did not inhibit
pAlu-induced RPE degeneration in wild-type mice (FIG.
2C). These data dismiss the possibility that TLR4-activating
lipopolysaccharide contamination induced the observed
RPE cell death. Furthermore, two different in vitro tran-
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scribed Alu RNAs (Kaneko et al., 2011) did not activate
TLR-2, 3, 4, 5, 7, 8, or 9 in a reporter assay system based in
human embryonic kidney 293 cells expressing each of the
TLRs (FIG. lF).
Because Alu RNA induced RPE degeneration independent of TLR activation, whether other dsRNA sensors such
as melanoma-differentiation-associated gene 5 (MDA5,
(Kato et al., 2006)) or protein kinase R (PKR, encoded by
Prkr, (Yang et al., 1995)) might mediate Alu RNA toxicity
was tested. However, pAlu induced RPE degeneration in
both Mda5 and Prkr_;_ mice (FIGS. 2D and 2E). The
possibility was evaluated that the 5'-triphosphate on in vitro
transcribed Alu RNA, which could potentially activate other
immune sensors such as retinoic acid inducible gene I
(RIG-I) or interferon-induced protein with tetratricopeptide
repeats 1 (IFIT-1) that can sense this moiety (Hornung et al.,
2006; Pichlmair et al., 2011), might be responsible for RPE
degeneration. Dephosphorylated Alu RNA induced RPE
degeneration in wild-type mice just as well as Alu RNA that
had not been subjected to dephosphorylation (FIG. 2F),
indicating that the presence of this chemical group is not
responsible for the observed cell death in vivo. Indeed, it has
been recently shown that a 5'-triphosphate ssRNA that
activates RIG-I does not induce RPE degeneration in mice
(Kleinman et al., 2011). Supportive of these findings, pAlu
induced RPE degeneration in mice deficient in mitochon
drial antiviral signaling protein (MAYS) (FIG. 2G), an
adaptor protein through which RIG-I and MDA-5 signal
(Kumar et al., 2006; Sun et al., 2006). Collectively these
data pointed to a novel mechanism of Alu RNA-induced
RPE degeneration not mediated by a wide range of canoni
cal RNA sensors.
Alu RNA Cytotoxicity is Mediated Via MyD88 and
IL-18.
The potential involvement of TRIF (encoded by Ticaml),
an adaptor protein for TLR3 and TLR4 was tested (Hoebe et
al., 2003; Yamamoto et al., 2003), and myeloid differentia
tion primary response protein (MyD88), an adaptor protein
for all TLRs except TLR3 was also tested (Akira et al., 2006;
Alexopoulou et al., 2001; Suzuki et al., 2003). Subretinal
administration of Alu RNA induced RPE degeneration in
Ticaml-I- mice (FIG. 4A), consistent with the findings in
Tlr3_1_ and Tlr4_1_ mice. Unexpectedly however, neither Alu
RNA nor two different pAlu plasmids induced RPE degeneration in Myd88-1- mice (FIGS. 3A, 48, and 4C). To
corroborate these genetic findings, pharmacological inhibi
tion of MyD88 was tested. Intravitreous administration of a
peptide inhibitor of MyD88 homodimerization (Loiarro et
al., 2005) prevented RPE degeneration induced by subretinal
administration of Alu RNA in wild-type mice, whereas a
control peptide did not impart protection (FIG. 38). A
MyD88-targeting short interfering RNA (siRNA) was
tested, which was shorter than 21 nucleotides in length to
prevent TLR3 activation and conjugated to cholesterol to
enable cell permeation (Kleinman et al., 2008). MyD88
siRNA inhibited RPE degeneration induced by pAlu in
wild-type mice, whereas a control siRNA did not do so
(FIGS. 3C-3E). Myd88+1- heterozygous mice were pro
tected against Alu RNA-induced RPE degeneration (FIGS.
3F and 4D), corroborating the findings from the siRNA
studies that partial knockdown of MyD88 is therapeutically
sufficient.
MyD88-mediated signal transduction induced by inter
leukins leads to recruitment and phosphorylation of the
IL-IR-associated kinases IRAKl and IRAK4 (Cao et al.,
1996; Kanakaraj et al., 1999; Suzuki et al., 2003; Suzuki et
al., 2002). Alu RNA increased phosphorylation of IRAKl/4
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in human RPE cells (FIG. 3G), supporting the concept that
Alu RNA triggers MyD88 signaling. The MyD88 inhibitory
peptide reduced Alu RNA-induced phosphorylation of
IRAKl/4 in human RPE cells (FIG. 4E), confirming its
mechanism of action in this model.
Next it was assessed whether MyD88 activation mediates
Alu RNA-induced cell death in human and mouse RPE cell
culture systems. In congruence with the in vivo data, pAlu
transfection reduced cell viability in wild-type but not
Mydss-1- mouse RPE cells (FIG. 3H). The MyD88-inhibi
tory peptide, but not a control peptide, inhibited cell death in
human RPE cells transfected with pAlu (FIG. 31). Taken
together, these data indicate that MyD88 is a critical mediator of Alu RNA-induced RPE degeneration.
MyD88 is generally considered an adaptor of innate
immune cells (O'Neill and Bowie, 2007). However, Alu
RNA induced cell death via MyD88 in RPE monoculture
systems. Therefore, it was determined whether Alu RNA
induced RPE degeneration in mice was also dependent
solely on MyD88 activation in RPE cells or whether it
required MyD88 activation in innate immune cells. To
determine the cell population that is critical for MyD88dependent RPE cell death, "foxed" MyD88 mice were
studied, as well as generated MyD88 bone marrow chime
ras. Conditional ablation ofMyD88 in the RPE by subretinal
injection of AAVl-BESTl-Cre in MydSst"f mice protected
against Alu RNA-induced RPE degeneration (FIGS. 3J and
4F). Consistent with this finding, Alu RNA induced RPE
degeneration in wild-type mice receiving Mydss-1- bone
marrow but did not do so in Mydss-1- mice receiving
wild-type bone marrow (FIG. 4G). Collectively, these
results indicate that MyD88 expression in the RPE, and not
in circulating immune cells, is critical for Alu RNA-induced
RPE degeneration. These findings comport with histopatho
logical studies of human GA tissue that show no infiltration
of immune cells in the area of pathology (personal commu
nication, C. A. Curcio, H. E. Grossniklaus, G. S. Hageman,
L. V. Johnson).
Although MyD88 is critical in TLR signaling (O'Neill
and Bowie, 2007), activation of MyD88 by Alu RNA
appeared to be independent of TLR activation. Thus, other
potential mechanisms of MyD88 involvement were exam
ined. MyD88 can regulate interferon gamma (IFN-y) sig
naling by interacting with IFN-y receptor 1 (encoded by
Ifngrl) (Sun and Ding, 2006). However, pAlu induced RPE
degeneration in both Ifng_;_ and Ifngrl-/- mice (FIGS. 4H
and 41). MyD88 is also essential in interleukin-I (IL-1)
signaling (Muzio et al., 1997). Therefore, it was tested
whether IL-1� and the related cytokine IL-18, both ofwhich
activate MyD88 (Adachi et al., 1998), were involved in
mediating Alu RNA cytotoxicity. Interestingly, whereas Alu
RNA overexpression in human RPE cells increased IL-18
secretion, IL-1� secretion was barely detectable (FIG. 3K).
Recombinant IL-18 induced RPE degeneration in wild
type but not Mydss-1- mice (FIG. 3L). A neutralizing
antibody against IL-18 protected against pAlu-induced RPE
degeneration in wild-type mice, whereas IL-1� neutraliza
tion provided no benefit (FIGS. 3M and 3N). Supporting
these findings, pAlu induced RPE degeneration in Illrl-1mice but not Il18r1_1_ mice (FIGS. 41 and 4K). These data
indicate that IL-18 is an important effector of Alu RNA
induced cytotoxicity.
Alu RNA activates the NLRP3 inflammasome.
Whether Caspase-1 (encoded by Caspi), a protease that
can catalyze cleavage of the pro-forms of interleukins to
their biologically active forms (Ghayur et al., 1997; Gu et
al., 1997; Thornberry et al., 1992), was involved in Alu
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RNA-induced RPE degeneration was explored. Alu RNA
treatment ofhuman RPE cells led to Caspase-1 activation as
measured by western blot analysis and by a fluorescent
reporter of substrate cleavage (FIGS. SA and 6A). Indeed,
Alu RNA induced Caspase-1 activation in other cell types
such as HeLa and THP-1 monocytic cells (FIG. 68), sug
gesting that the cytotoxicity of Alu RNA has potentially
broad implications in many systems. Intravitreous adminis
tration ofthe Caspase-1-inhibitory peptide Z-WEHD-FMK,
but not a control peptide Z-FA-FMK, blocked IL-18 matu
ration and pAlu-induced RPE degeneration in wild-type
mice (FIGS. SB and SC). The Caspase-1-inhibitory peptide
blocked Alu RNA-induced substrate cleavage in human RPE
cells (FIG. 6C), confirming its mechanism of action in this
system. These findings were corroborated by the absence of
RPE degeneration in Caspi-I- mice treated with Alu RNA or
pAlu (FIGS. SD and 6D). Also, pAlu did not induce cell
death in Casp1-1- mouse RPE cells (FIG. SE).
Caspase-1 can be activated within a multiprotein innate
immune complex termed the inflammasome (Tschopp et al.,
2003). The best-characterized inflammasome pathway is one
that is activated by binding of NLRP3 (nucleotide-binding
domain, leucin-rich-containing family, pyrin domain-con
taining-3) to the caspase-1 adaptor apoptosis-associated
speck-like protein containing a caspase-recruitment domain
(ASC; encoded by PYCARD).
To assess whether Alu RNA induced inflammasome
assembly, human RPE cells were transfected with a vector
encoding a fusion protein ofPYCARD and green fluorescent
protein (GFP-PYCARD), which enabled spatial clustering
of PYCARD that occurs upon PYCARD activation in cell
culture to be optically-monitored (Fernandes-Alnemri et al.,
2007). Alu RNA induced the appearance of a brightly
fluorescent cluster of GFP-PYCARD visible in the cyto
plasm similar to treatment with LPS and ATP, which is
known to activate the NLRP3 inflammasome (FIGS. SF and
6E) (Mariathasan et al., 2006).
Next the functional relevance ofNLRP3 and PYCARD to
Alu RNA cytotoxicity was tested using genetic and phar
macological inhibition. Neither pAlu nor Alu RNA induced
RPE degeneration in either Nlrp3_1_ or Pycard-1- mice
(FIGS. SG, SH, 6F and 6G), demonstrating the critical
importance of the inflammasome in transducing the cyto
toxicity of Alu RNA. It was also found that pAlu did not
induce cell death in Nlrp3_1_ or Pycard-1- mouse RPE cells
(FIG. SI). Moreover, knockdown ofNLRP3 or PYCARD by
siRNAs rescued pAlu-induced human RPE cell death
(FIGS. SJ and 6H). These findings provide direct evidence
that NLRP3 activation in response to Alu RNA occurs in
RPE cells and does not require the presence ofother immune
cells.
It was determined that IL-18 and MyD88 activation
indeed were downstream of Caspase-1 activation by show
ing (1) that whereas the MyD88 inhibitory peptide reduced
Alu RNA-induced phosphorylation of IRAKl/4 in human
RPE cells (FIG. 4E), it did not reduce Alu RNA-induced
Caspase-1 cleavage or fluorescent substrate cleavage (FIGS.
61 and 6J); (2) that IL-18 neutralizing antibodies did not
inhibit Alu RNA-induced Caspase-1 cleavage (FIGS. 6K);
and (3) that the Caspase-1 inhibitory peptide reduced Alu
RNA-induced phosphorylation of IRAKl/4 (FIG. 6L).
NLRP3 inflammasome function is thought to require two
signals, the first of which is termed priming. pAlu induced
inflammasome priming as it upregulated both NLRP3 and
ILi8 mRNAs. This priming occurred equivalently in both
wild-type and Mydss-1- mouse RPE cells (FIG. 7A), further
corroborating that MyD88 functions downstream ofNLRP3
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in this system. pAlu induced the generation of reactive
oxygen species (ROS) (FIG. 78), a signal for NLRP3
priming (Bauernfeind et al., 2011; Nakahira et al., 2011),
and the ROS inhibitor APDC blocked pAlu-induced NLRP3
and IL18 mRNA upregulation (FIG. 7C). Consistent with
these data, APDC blocked pAlu-induced RPE degeneration
in wild-type mice (FIG. 7D).
NLRP3 inflammasome activation is also known to
involve the ATP-gated channel P2X7 (encoded by P2RX7),
whose activation leads to cellular efflux ofK+ (Mariathasan
et al., 2004). As disclosed herein, P2rx1-1- mice were
protected against pAlu-induced RPE degeneration and the
P2X7 receptor antagonist A438079 blocked pAlu-induced
RPE degeneration in wild-type mice (FIGS. 7E and 7F).
Consonant with these data, pAlu-induced RPE degeneration
in wild-type mice was inhibited by glyburide, which func
tions downstream ofP2X7 to block NLRP3 activation (Lam
kanfi et al., 2009), but not by the closely related glipizide,
which does not block NLRP3 (FIG. 7G).
IL-18 and MyD88 Induces RPE Degeneration Via Caspase-3.
The mode ofcell death in Alu RNA-induced RPE degen
eration mediated via IL-18 activation ofMyD88 was sought
to be determined. Alu RNA activates Caspase-1, which can
trigger pyroptosis, a form of cell death characterized by
formation of membrane pores and osmotic lysis (Fink and
Cookson, 2006). It was found that the cytoprotective agent
glycine, which can attenuate pyroptosis (Fink et al., 2008;
Fink and Cookson, 2006; Verhoef et al., 2005), inhibited
human RPE cell death induced by LPS+ATP but not by Alu
RNA (FIGS. SA and SB). Pyroptosis requires Caspase-1 but
can proceed independent of IL-18 (Miao et al., 2010).
Therefore, the finding that IL-18 induced RPE degeneration
in Casp1-1- mice (FIG. SC), coupled with the lack ofrescue
by glycine, suggests that Alu RNA-induced RPE degeneration does not occur via pyroptosis.
It was reported earlier that Alu RNA activates Caspase-3
(Kaneko et al., 2011), an executioner protease associated
with apoptosis. In wild-type mice, IL-18 induced Caspase-3
activation in the RPE (FIG. SD), and the Caspase-3 inhibitor
Z-DEVD-FMK blocked IL-18-induced RPE degeneration
(FIG. SE). Because IL-18 induces RPE degeneration in mice
via MyD88, it was tested whether MyD88 inhibition also
blocks Caspase-3 activation. Indeed, the MyD88 inhibitory
peptide inhibited Alu RNA-induced Caspase-3 activation in
the RPE of wild-type mice (FIG. SF). Collectively, these
data point towards apoptosis as the mode ofcell death in Alu
RNA-induced RPE degeneration, and are consistent with
other systems wherein IL-18 and MyD88 induce apoptosis
(Aliprantis et al., 2000; Chandrasekar et al., 2004; Ohtsuki
et al., 1997). These findings are also compatible with the
observations of Caspase-3 activation (Kaneko et al., 2011)
and apoptosis (Dunaief et al., 2002) in RPE cells in human
GA.
DICER! Loss Induces Cell Death Via Inflammasome.
It has been demonstrated that the key role ofDICER! in
maintaining RPE cell health (Kaneko et al., 2011): DICERl
cleaved Alu RNA did not induce RPE degeneration in vivo;
DICER! overexpression protected against Alu RNA-in
duced RPE degeneration; and DICER! loss-induced RPE
degeneration was blocked by antisense oligonucleotides
targeting Alu RNA (Kaneko et al., 2011). Also, rescue of
DICER! knockdown-induced RPE degeneration by Alu
RNA inhibition was not accompanied by restoration of
microRNA deficits (Kaneko et al., 2011). Therefore, it was
tested whether DICER! also prevented NLRP3 inflam
masome activation by Alu RNA. Alu RNA-induced Cas-
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pase-1 activation in human RPE cells, as monitored by
western blot analysis and by a fluorescent reporter of sub
strate cleavage, was inhibited by DICER! overexpression
(FIGS. 6A and 68). Conversely, Caspase-1 cleavage
induced by DICER! knockdown in human RPE cells, as
monitored by immunofluorescence assay, was inhibited by
simultaneous antisense-mediated knockdown of Alu RNA
(FIGS. lOA and 108).
Next the in vivo functional relevance of these pathways
was tested in the context ofDICER! loss in vivo. Caspase-1l
cleavage was increased in the RPE ofBEST! Cre; Dicer]ff
mice (FIG. 9C), which lose DICER! expression in the RPE
during development and exhibit RPE degeneration (Kaneko
et al., 2011). Subretinal delivery of AAVl-BESTl-Cre in
Dicer]flfmice induced Caspase-1 activation and IL-18 matu
ration in the RPE (FIG. 9D). This treatment also induced
RPE degeneration, which was blocked by intravitreous
administration of the Caspase-1-inhibitory peptide but not
the control peptide (FIG. 9E).l AAVl-BESTl-Cre-induced
RPE degeneration in Dicer]ff mice was also blocked by
intravitreous administration of the MyD88-inhibitory peptide but not a control peptide (FIG. 9F). In addition, the
MyD88-inhibitory peptide prevented cell death in human
RPE cells treated with antisense oligonucleotides targeting
DICER! (FIG. 9G). DICER! knockdown in human RPE
cells increased phosphorylation ofIRAKl/4, providing further evidence of MyD88 activation upon loss of DICER!
(FIG. 9H). The MyD88-inhibitory peptide also prevented
cell death in Dicer]flf mouse RPE cells treated with an
adenoviral vector coding for Cre recombinase (FIG. 91).
MyD88 inhibition blocked RPE cell death without restoring
the microRNA expression deficits induced by Dicer! knock
down (FIG. 91). These findings demonstrate that DICER! is
an essential endogenous negative regulator of NLRP3
inflammasome activation, and that DICER! deficiency leads
to Alu RNA-mediated, MyD88-dependent, microRNA-independent RPE degeneration.
Inflammasome and MyD88 Activation in Human GA.
Next, it was determined whether human eyes with GA,
which exhibit loss of DICER! and accumulation of Alu
RNA in their RPE (Kaneko et al., 2011), also display
evidence of inflammasome activation. The abundance of
NLRP3 mRNA in the RPE of human eyes with GA was
markedly increased compared to control eyes (FIG. llA), as
monitored by real-time RT-PCR. IL18 and ILlB mRNA
abundance also was increased in GA RPE; however, only the
disparity in ILi 8 levels reached statistical significance (FIG.
llA). Immunolocalization studies showed that the expres
sion ofNLRP3, PYCARD, and Caspase-1 proteins was also
increased in GA RPE (FIGS. 118-D). Western blot analyses
corroborated the increased abundance of NLRP3 and
PYCARD in GA RPE, and revealed greatly increased levels
of the enzymatically active cleaved Caspase-1 p20 subunit
in GA RPE (FIG. llE). There was also an increase in the
abundance of phosphorylated IRAKl and IRAK4 in GA
RPE, indicative of increased MyD88 signal transduction
(FIG. llE). Collectively, these data provide evidence of
NLRP3 inflammasome and MyD88 activation in situ in
human GA, mirroring the functional data in human RPE cell
culture and mice in vivo.
DISCUSSION

65

The data presented herein establish a functional role for
the subversion of innate immune sensing pathways by
repetitive element transcripts in the pathogenesis of GA.
Collectively, the findings demonstrate that the NLRP3
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inflammasome senses GA-associated Alu RNA danger sig
nals, contributes to RPE degeneration, and potentially vision
loss in AMD. To date, the function of the NLRP3 inflam
masome has been largely restricted to immune cells in vivo.
The finding that it plays a critical function in RPE cell
survival broadens the cellular scope of this inflammasome
and raises the possibility that other non-immune cells could
employ this platform.
The NLRP3 inflammasome was originally recognized as
a sensor of external danger signals such as microbial toxins
(Karmeganti et al., 2006; Mariathasan et al., 2004; Mari
athasan et al., 2006; Muruve et al., 2008). Subsequently,
endogenous crystals, polypeptides, and lipids were reported
to activate it in diseases such as gout, atherogenesis,
Alzheimer disease, and Type 2 diabetes (Halle et al., 2008;
Masters et al., 2010: Muruve et al, 2008; Vandanmagsar et
al., 2011; Wen et al, 2011). To the Applicant's knowledge,
Alu RNA is the first endogenous nucleic acid known to
activate this immune platform. The findings disclosed herein
expand the diversity of endogenous danger signals in
chronic human diseases, and comport with the concept that
this inflammasome is a sensor of metabolic danger (Schro
der et al., 2010).
Dampening inflammasome activation can be essential to
limiting the inflanmiatory response. Pathogens have evolved
many strategies to inhibit inflammasome activation (Mara
nan et al., 2009). Likewise, host autophagy proteins (Naka
hira et al., 2011; Saitoh et al., 2008), Type I interferon
(Guarda et al., 2011), and T cell contact with macrophages
can inhibit this process (Guarda et al., 2009). The finding
that DICER!, through its cleavage of retrotransposon tran
scripts, prevents activation of the NLRP3 inflammasome
adds to the repertoire of host inflanmiasome modulation
capabilities and reveal a new facet of how dysregulation of
homeostatic anti-inflammatory mechanisms can promote
AMD (Ambati et al., 2003; Takeda et al., 2009).
Added to its recently described anti-apoptotic and tumor
related functions, DICER! emerges as a multifaceted pro
tein. It remains to be determined how this functional versa
tility is channeled in various states. As DICER!
dysregulation is increasingly recognized in several human
diseases, it is reasonable to imagine that Alu RNA might be
an inflanmiasome activating danger signal in those condi
tions too. It is also interesting that, at least in adult mice and
in a variety of mouse and human cells, the microRNA
biogenesis function of DICER! is not critical for cell
survival, at least in a MyD88-deficient environment (data
not shown).
Although DICER! levels are important in maintaining
RPE cell health by metabolizing Alu RNA, other nucleases
also may regulate Alu RNA. For example, Alu is a ret
rotransposon that can form RNA-DNA replication interme
diates, which would be substrates for RNase H. Indeed,
RNase H inhibits retrotransposition (Ma and Crouch, 1996),
and human enzymes such as LINE-I (Dhellin et al., 1997;
McClure, 1991) contain an RNase H domain. The Argo
naute-related PIWI family ofnucleases (Parker et al., 2004)
also contain an RNase H domain, though it is not known
whether the human homolog HIWI degrades retrotranspo
son intermediates. Other enzymes such as the PIWI-related
MIWI in mice also directly cleave retrotransposon RNA
(Reuter et al., 2011 ). Thus, it is likely that DICER! is one of
several mechanisms by which cells regulate retrotransposon
expression.
Current clinical programs targeting the inflammasome
largely focus on IL-1�; presently there are no IL-18 inhibi
tors in registered clinical trials. However, the data indicate
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that IL-18 is more important than IL-1� in mediating RPE
cell death in GA (similar to selective IL-18 involvement in
a colitis model (Zaki et al., 2010)), pointing to the existence
ofas yet unknown regulatory mechanisms by which inflam
masome activation bifurcates at the level ofor just preceding
the interleukin effectors. Although Caspase-1 inhibition
could be an attractive local therapeutic strategy, caspase
inhibitors can promote alternative cell death pathways, pos
sibly limiting their utility (Vandenabeele et al., 2006).
MyD88 is best known for transducing TLR signaling
initiated by pathogen associated molecular patterns (O'Neill
and Bowie, 2007), although recently it has been implicated
in human cancers (Ngo et al., 2011; Puente et al., 2011;
Rakoff-Nahoum and Medzhitov, 2007). The findings intro
duce an unexpected new function for MyD88 in effecting
death signals from mobile element transcripts that can lead
to retinal degeneration and blindness, and raise the possi
bility that MyD88 could be a central integrator of signals
from other non-NLRP3 inflammasomes that also employ
Caspase-1 (Schroder and Tschopp, 2010). Since non-canoni
cal activation of MyD88 is a critical checkpoint in RPE
degeneration in GA (FIG. 12), it represents an enticing
therapeutic target. A potential concern is its important anti
microbial function in mice (O'Neill and Bowie, 2007).
However, in contrast to Myd88_1_ mice, adult humans with
MyD88 deficiency are described to be generally healthy and
resistant to a wide variety of microbial pathogens (von
Bernuth et al., 2008). MyD88-deficient humans have a
narrow susceptibility range to pyogenic bacterial infections,
and that too only in early childhood and not adult life (Picard
et al., 2010). Moreover, as evident from the siRNA and
Myd88 studies, partial inhibition of MyD88 is sufficient to
protect against Alu RNA. Localized intraocular therapy, the
current standard of care in most retinal diseases, would
further limit the likelihood of adverse infectious outcomes.
It is reasonable to foresee development ofMyD88 inhibitors
for prevention or treatment of GA.
Example 2
It has been have shown that Alu RNA induces RPE
degeneration via MyD88 signaling, and that Alu RNA
increases phosphorylation of IRAKl and IRAK4, kinases
downstream of MyD88. To determine whether IRAKl/
IRAK4 phosphorylation is critical to Alu RNA-induced RPE
degeneration,
N-(2-Morpholinylethyl)-2-(3-nitrobenzoylamido)-benzimidazole, an IRAK/4 inhibitor, was tested.
Indeed it was found that this IRAK/4 inhibitor blocked Alu
RNA-induced RPE degeneration in wild-type mice in a
dose-dependent manner (FIG. 13). With reference to FIG.
13, Alu RNA was injected subretinally in wild-type mice to
induce RPE degeneration. Compared to vehicle administra
tion, intravitreous administration ofan inhibitor ofIRAKl/4
reduced the RPE degeneration induced by Alu RNA in a
dose-dependent fashion (1.5-15 µg). With reference to FIG.
14, exposure ofhuman RPE cells to an inhibitor ofIRAKl/4
rescued the cell death induced by transfection ofpAlu. With
reference to FIG. 15, exposure of human RPE cells to an
inhibitor of IRAKl/4 rescued the cell death induced by
transfection of Alu RNA.
As noted herein, methods disclosed in the present appli
cation can be useful for treating all forms of macular
degeneration, including the wet form of macular degenera
tion (e.g., angiogenesis/blood vessel growth). By way of
specific example, a MyD88 inhibitor can be used to treat
various forms of macular degeneration, and is specifically
contemplated for inhibition ofchoroidal neovascularization.

25

US 9,707,235 Bl

Relevant data are set forth in FIGS. 16-19. FIG. 16 is a bar
graph showing that MyDss-1- mice have reduced laser
induced choroidal neovascularization as compared to wild
type mice. FIG. 17 is a bar graph showing that intravitreous
injection of a peptide MyD88 inhibitor reduced laser-induced choroidal neovascularization in wild-type mice com
pared to a control peptide inhibitor. FIG. 18 is a bar graph
showing that intravitreous injection of an siRNA targeting
MyD88 (2 µg) reduced laser-induced choroidal neovascu
larization in wild-type mice at least as well as a neutralizing
anti-mouse V EGF antibody, compared to a control sirRNA.
FIG. 19 is a bar graph showing that intravitreous injection of
an inhibitor of IRAKl/4 reduced laser-induced choroidal
neovascularization in wild-type mice compared to vehicle.
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What is claimed is:
1. A method of treating dry macular degeneration, com
prising:
(a) identifying a subject in need of treatment for dry
macular degeneration; and
(b) administering a composition to the subject the com
position binding with MyD88 in an retinal pigmented
epithelium (RPE) cell of the subject to inhibit the
MyD88; with IL-18 in an RPE cell of the subject to
inhibit the IL-18; or with NLRP3 inflammasome, or
Caspase-1 in an RPE cell of the subject to inhibit the
inflannnasome.
2. The method of claim 1, wherein the composition
comprises MyD88 siRNA.
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